Til StÃ¼rmer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6800020/publications.pdf

Version: 2024-02-01

261 papers	14,601 citations	28274 55 h-index	22166 113 g-index
271 all docs	271 docs citations	271 times ranked	18163 citing authors

#	Article	IF	Citations
1	Variable Selection for Propensity Score Models. American Journal of Epidemiology, 2006, 163, 1149-1156.	3.4	1,618
2	Doubly Robust Estimation of Causal Effects. American Journal of Epidemiology, 2011, 173, 761-767.	3.4	671
3	A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. Journal of Clinical Epidemiology, 2006, 59, 437.e1-437.e24.	5.0	557
4	Indications for Propensity Scores and Review of their Use in Pharmacoepidemiology. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 253-259.	2.5	474
5	Propensity Score Methods for Confounding Control in Nonexperimental Research. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 604-611.	2.2	435
6	The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. Current Epidemiology Reports, 2015, 2, 221-228.	2.4	407
7	Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1611.	7.4	392
8	Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study. American Journal of Epidemiology, 2010, 172, 843-854.	3.4	343
9	Association Between the Choice of IV Crystalloid and In-Hospital Mortality Among Critically Ill Adults With Sepsis*. Critical Care Medicine, 2014, 42, 1585-1591.	0.9	340
10	Confounding Control in Healthcare Database Research. Medical Care, 2010, 48, S114-S120.	2.4	291
11	Obesity, overweight and patterns of osteoarthritis. Journal of Clinical Epidemiology, 2000, 53, 307-313.	5.0	290
12	Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study. Annals of Internal Medicine, 1998, 128, 713.	3.9	254
13	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1141.	7.4	250
14	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. Medical Care, 2007, 45, S131-S142.	2.4	228
15	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	12.8	216
16	Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. Journal of Clinical Oncology, 2012, 30, 2624-2634.	1.6	215
17	Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. Journal of Internal Medicine, 2014, 275, 570-580.	6.0	214
18	Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry,the, 2018, 5, 824-835.	7.4	187

#	Article	IF	Citations
19	Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration. American Journal of Epidemiology, 2005, 162, 279-289.	3.4	185
20	The incident user design in comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2013, 22, 1-6.	1.9	181
21	Opioid Analgesics and the Risk of Fractures in Older Adults with Arthritis. Journal of the American Geriatrics Society, 2011, 59, 430-438.	2.6	176
22	Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 835-842.	3.6	168
23	Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Annals of the Rheumatic Diseases, 2004, 63, 200-205.	0.9	160
24	Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. American Journal of Epidemiology, 2005, 161, 891-898.	3.4	155
25	Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiology and Drug Safety, 2015, 24, 59-66.	1.9	132
26	Individual and joint contribution of family history andHelicobacter pylori infection to the risk of gastric carcinoma. Cancer, 2000, 88, 274-279.	4.1	129
27	The role of the câ€statistic in variable selection for propensity score models. Pharmacoepidemiology and Drug Safety, 2011, 20, 317-320.	1.9	128
28	Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. JAMA Pediatrics, 2015, 169, 452.	6.2	119
29	Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2391-2397.	2.5	113
30	An Epidemiologic Study of Abuse of Analgesic Drugs. New England Journal of Medicine, 1991, 324, 155-160.	27.0	111
31	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiology and Drug Safety, 2011, 20, 551-559.	1.9	111
32	Trends in Prevalence and Determinants of Potentially Inappropriate Prescribing in the United States: 2007 to 2012. Journal of the American Geriatrics Society, 2016, 64, 788-797.	2.6	105
33	Performance of Propensity Score Calibration--A Simulation Study. American Journal of Epidemiology, 2007, 165, 1110-1118.	3.4	101
34	Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiology and Drug Safety, 2006, 15, 698-709.	1.9	96
35	Provider Delay Among Patients With Breast Cancer in Germany: A Population-Based Study. Journal of Clinical Oncology, 2003, 21, 1440-1446.	1.6	92
36	Personality, lifestyle, and risk of cardiovascular disease and cancer: follow-up of population based cohort. BMJ: British Medical Journal, 2006, 332, 1359.	2.3	92

#	Article	IF	Citations
37	Comparative Effectiveness of Oxaliplatin vs Nonâ€“Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 211-227.	6.3	90
38	A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2792-2798.	3.6	86
39	Pain and high sensitivity C reactive protein in patients with chronic low back pain and acute sciatic pain. Annals of the Rheumatic Diseases, 2005, 64, 921-925.	0.9	82
40	Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture. Annals of Internal Medicine, 2008, 148, 637.	3.9	82
41	Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiology and Drug Safety, 2010, 19, 1248-1255.	1.9	82
42	The Role of Prediction Modeling in Propensity Score Estimation: An Evaluation of Logistic Regression, bCART, and the Covariate-Balancing Propensity Score. American Journal of Epidemiology, 2014, 180, 645-655.	3.4	81
43	Trends in Glyburide Compared With Insulin Use for Gestational Diabetes Treatment in the United States, 2000â€“2011. Obstetrics and Gynecology, 2014, 123, 1177-1184.	2.4	79
44	Antidepressant Dose, Age, and the Risk of Deliberate Self-harm. JAMA Internal Medicine, 2014, 174, 899.	5.1	76
45	Comparative Safety of Testosterone Dosage Forms. JAMA Internal Medicine, 2015, 175, 1187.	5.1	76
46	Caseâ€“crossover and caseâ€“timeâ€“control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	73
47	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. American Journal of Epidemiology, 2009, 169, 909-917.	3.4	71
48	Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiology and Drug Safety, 2013, 22, 77-85.	1.9	71
49	Considerations for Pharmacoepidemiological Studies of Drugâ€“Cancer Associations. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 451-459.	2.5	70
50	Treating Depression After Initial Treatment Failure. Journal of Clinical Psychopharmacology, 2012, 32, 114-119.	1.4	69
51	Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. Medical Care, 2007, 45, S158-S165.	2.4	68
52	Nocturnal sleep duration and cognitive impairment in a populationâ€based study of older adults. International Journal of Geriatric Psychiatry, 2010, 25, 100-109.	2.7	68
53	Identifying Specific Chemotherapeutic Agents in Medicare Data. Medical Care, 2013, 51, e27-e34.	2.4	68
54	Nonexperimental Comparative Effectiveness Research Using Linked Healthcare Databases. Epidemiology, 2011, 22, 298-301.	2.7	64

#	Article	IF	Citations
55	Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014. JAMA Psychiatry, 2017, 74, 747.	11.0	64
56	Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study*. Inflammatory Bowel Diseases, 2012, 18, 1048-1056.	1.9	61
57	Socio-demographic factors, health behavior and late-stage diagnosis of breast cancer in Germany. Journal of Clinical Epidemiology, 2001, 54, 719-727.	5.0	57
58	Effect of Statin Use on Acute Kidney Injury Risk Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2013, 111, 823-828.	1.6	56
59	Lumbar spine radiographic features and demographic, clinical, and radiographic knee, hip, and hand osteoarthritis. Arthritis Care and Research, 2012, 64, 1536-1544.	3.4	53
60	The course of high-sensitive C-reactive protein in correlation with pain and clinical function in patients with acute lumbosciatic pain and chronic low back pain-A 6 months prospective longitudinal study. European Journal of Pain, 2006, 10, 711-711.	2.8	51
61	Association Between Postoperative Delirium and Long-term Cognitive Function After Major Nonemergent Surgery. JAMA Surgery, 2019, 154, 328.	4.3	51
62	Calendar timeâ€specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiology and Drug Safety, 2013, 22, 810-818.	1.9	50
63	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. Journal of the American Society of Nephrology: JASN, 2016, 27, 3129-3138.	6.1	50
64	Methodological considerations when analysing and interpreting real-world data. Rheumatology, 2020, 59, 14-25.	1.9	50
65	Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in Medicine, 2021, 40, 1718-1735.	1.6	50
66	Caseâ€“crossover and caseâ€“timeâ€“control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	48
67	Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiology and Drug Safety, 2010, 19, 2-9.	1.9	47
68	Construction Work and Low Back Disorder. Spine, 1997, 22, 2558-2563.	2.0	46
69	Sedation, Analgesia, and Paralysis during Mechanical Ventilation of Premature Infants. Journal of Pediatrics, 2017, 180, 99-104.e1.	1.8	46
70	Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. American Journal of Medicine, 2001, 111, 521-527.	1.5	44
71	Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiology and Drug Safety, 2013, 22, 122-129.	1.9	44
72	Obesity and Adult Asthma: Potential Effect Modification by Gender, But Not by Hay Fever. Annals of Epidemiology, 2008, 18, 283-289.	1.9	43

#	Article	IF	Citations
73	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodiumâ€“Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. Diabetes Care, 2021, 44, 1564-1572.	8.6	43
74	Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding. Clinical Epidemiology, 2017, Volume 9, 611-626.	3.0	41
75	Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. Diabetes Care, 2013, 36, 3517-3525.	8.6	40
76	Comparative Effectiveness of Intensity-Modulated Radiotherapy and Conventional Conformal Radiotherapy in the Treatment of Prostate Cancer After Radical Prostatectomy. JAMA Internal Medicine, 2013, 173, 1136.	5.1	40
77	Metformin and the risk of endometrial cancer: A population-based cohort study. Gynecologic Oncology, 2015, 136, 341-347.	1.4	40
78	SSRI use and risk of fractures among perimenopausal women without mental disorders. Injury Prevention, 2015, 21, 397-403.	2.4	40
79	Depressive Symptoms, Social Support, and Risk of Adult Asthma in a Population-Based Cohort Study. Psychosomatic Medicine, 2010, 72, 309-315.	2.0	39
80	Calcium Gluconate in Severe Verapamil Intoxication. New England Journal of Medicine, 1994, 330, 718-720.	27.0	38
81	Real-world evidence: the devil is in the detail. Diabetologia, 2020, 63, 1694-1705.	6.3	38
82	Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Injury Prevention, 2013, 19, 164-170.	2.4	37
83	Direct, Indirect, Total, and Overall Effectiveness of the Rotavirus Vaccines for the Prevention of Gastroenteritis Hospitalizations in Privately Insured US Children, 2007-2010. American Journal of Epidemiology, 2014, 179, 895-909.	3.4	37
84	Approaches to Antifungal Therapies and Their Effectiveness among Patients with Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2485-2495.	3.2	36
85	Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA Pediatrics, 2019, 173, 160.	6.2	36
86	Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. Gastrointestinal Endoscopy, 2019, 90, 360-369.	1.0	35
87	A Prospective Study of Blood Pressure and Risk of Cataract in Men. Annals of Epidemiology, 2001, 11, 104-110.	1.9	34
88	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiology and Drug Safety, 2020, 29, 9-17.	1.9	34
89	Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006â€“2010. PLoS ONE, 2013, 8, e73825.	2.5	33
90	Evidence of Sample Use Among New Users of Statins. Medical Care, 2014, 52, 773-780.	2.4	33

#	Article	IF	Citations
91	Flexible Matching Strategies to Increase Power and Efficiency to Detect and Estimate Gene-Environment Interactions in Case-Control Studies. American Journal of Epidemiology, 2002, 155, 593-602.	3.4	32
92	Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults. Epidemiology, 2018, 29, 556-561.	2.7	32
93	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care, 2018, 41, 1998-2009.	8.6	32
94	Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators. Pharmacoepidemiology and Drug Safety, 2022, 31, 261-269.	1.9	32
95	Serotoninâ€“Norepinephrine Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor Use and Risk of Fractures: A New-User Cohort Study Among US Adults Aged 50 Years and Older. CNS Drugs, 2015, 29, 245-252.	5.9	31
96	Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study. American Journal of Epidemiology, 2021, 190, 1659-1670.	3.4	31
97	Matching on the disease risk score in comparative effectiveness research of new treatments. Pharmacoepidemiology and Drug Safety, 2015, 24, 951-961.	1.9	29
98	Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 41-49.	2.5	29
99	The importance and implications of comparator selection in pharmacoepidemiologic research. Current Epidemiology Reports, 2018, 5, 272-283.	2.4	29
100	Sodiumâ€glucose coâ€transporterâ€2 inhibitor use and risk of lowerâ€extremity amputation: Evolving questions, evolving answers. Diabetes, Obesity and Metabolism, 2019, 21, 1223-1236.	4.4	29
101	Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. Journal of the American Society of Nephrology: JASN, 2019, 30, 346-353.	6.1	29
102	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
103	Diabetes and cognitive function in a population-based study of elderly women and men. Journal of Diabetes and Its Complications, 2006, 20, 238-245.	2.3	27
104	Treating Pediatric Anxiety. Journal of Clinical Psychiatry, 2018, 79, 16m11415.	2.2	27
105	Colorectal Cancer After Start of Nonsteroidal Anti-Inflammatory Drug Use. American Journal of Medicine, 2006, 119, 494-502.	1.5	26
106	A framework for understanding cancer comparative effectiveness research data needs. Journal of Clinical Epidemiology, 2012, 65, 1150-1158.	5.0	26
107	Effects of Combination Antiretroviral Therapies on the Risk of Myocardial Infarction Among HIV Patients. Epidemiology, 2014, 25, 406-417.	2.7	26
108	Data for cancer comparative effectiveness research. Cancer, 2012, 118, 5186-5197.	4.1	25

#	Article	IF	Citations
109	Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2014, 59, 1535-1543.	2.3	25
110	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. American Journal of Epidemiology, 2019, 188, 609-616.	3.4	25
111	Clinical Diagnosis of Ischemic versus Hemorrhagic Stroke: Applicability of Existing Scores in the Emergency Situation and Proposal of a New Score. Neuroepidemiology, 2002, 21, 8-17.	2.3	24
112	The Future of Epidemiology. Academic Medicine, 2009, 84, 1631-1637.	1.6	24
113	Tamoxifen Initiation After Ductal Carcinoma In Situ. Oncologist, 2016, 21, 134-140.	3.7	24
114	Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 728-737.	4.5	24
115	Propensity Score Calibration in the Absence of Surrogacy. American Journal of Epidemiology, 2012, 175, 1294-1302.	3.4	23
116	Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population. American Journal of Epidemiology, 2018, 187, 817-827.	3.4	23
117	The Performance of Methods for Correcting Measurement Error in Case-Control Studies. Epidemiology, 2002, 13, 507-516.	2.7	22
118	An Observational Study of Pharmacological Treatment in Primary Care of Children With ADHD in the United Kingdom. Psychiatric Services, 2015, 66, 617-624.	2.0	22
119	Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer, 2012, 118, 2925-2934.	4.1	21
120	Antihypertensive Adherence Trajectories Among Older Adults in the First Year After Initiation of Therapy. American Journal of Hypertension, 2017, 30, 1015-1023.	2.0	21
121	The Role of the <i>TPH1</i> and <i>TPH2</i> Genes for Nicotine Dependence: A Genetic Association Study in Two Different Age Cohorts. Neuropsychobiology, 2007, 56, 47-54.	1.9	20
122	Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Medical Research Methodology, 2013, 13, 142.	3.1	19
123	Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications. Journal of Affective Disorders, 2016, 196, 138-147.	4.1	19
124	Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiology and Drug Safety, 2019, 28, 1290-1298.	1.9	19
125	Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournierâ€™s gangrene. BMJ Open Diabetes Research and Care, 2020, 8, e000985.	2.8	19
126	Nonsteroidal anti-inflammatory drugs and the kidney. Current Opinion in Nephrology and Hypertension, 2001, 10, 161-163.	2.0	18

#	Article	IF	Citations
127	Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Psychiatric Services, 2016, 67, 302-309.	2.0	18
128	Childbearing is not associated with young women's longâ€term obesity risk. Obesity, 2014, 22, 1126-1132.	3.0	17
129	Reducing Bias Amplification in the Presence of Unmeasured Confounding through Out-of-Sample Estimation Strategies for the Disease Risk Score. Journal of Causal Inference, 2014, 2, 131-146.	1.2	17
130	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidaseâ€4 inhibitors vs therapeutic alternatives. Diabetes, Obesity and Metabolism, 2017, 19, 970-978.	4.4	17
131	Classifying medical histories in US Medicare beneficiaries using fixed vs allâ€available lookâ€back approaches. Pharmacoepidemiology and Drug Safety, 2018, 27, 771-780.	1.9	17
132	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. American Journal of Hypertension, 2019, 32, 1146-1153.	2.0	17
133	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. Diabetes Care, 2019, 42, e21-e23.	8.6	17
134	Relation among alcohol dehydrogenase 2 polymorphism, alcohol consumption, and levels of gamma-glutamyltransferase. Alcohol, 2003, 29, 131-135.	1.7	16
135	Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer, 2013, 119, 2038-2047.	4.1	16
136	Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults. Epidemiology, 2015, 26, 690-699.	2.7	16
137	Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. American Journal of Men's Health, 2016, 10, 399-407.	1.6	16
138	Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database. International Archives of Allergy and Immunology, 2017, 173, 51-60.	2.1	16
139	Reninâ€“Angiotensinâ€“Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries. Epidemiology, 2019, 30, 867-875.	2.7	16
140	Causeâ€specific mortality among Medicare beneficiaries with newly diagnosed nonâ€Hodgkin lymphoma subtypes. Cancer, 2019, 125, 1101-1112.	4.1	16
141	Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population. American Journal of Epidemiology, 2019, 188, 426-437.	3.4	16
142	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). Drugs - Real World Outcomes, 2022, , 1.	1.6	16
143	Potential gain in efficiency and power to detect gene-environment interactions by matching in case-control studies. , 2000, 18, 63-80.		15
144	Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort. Medical Care, 2015, 53, e41-e48.	2.4	15

#	Article	IF	Citations
145	Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium. PLoS ONE, 2015, 10, e0140496.	2.5	15
146	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology, 2017, 28, 446-454.	2.7	15
147	Controlling confounding by frailty when estimating influenza vaccine effectiveness using predictors of dependency in activities of daily living. Pharmacoepidemiology and Drug Safety, 2017, 26, 1500-1506.	1.9	15
148	The â€œDry-Runâ€•Analysis: A Method for Evaluating Risk Scores for Confounding Control. American Journal of Epidemiology, 2017, 185, 842-852.	3.4	15
149	Sturmer et al. Respond to "Propensity Score Methods in Epidemiology". American Journal of Epidemiology, 2007, 165, 1122-1123.	3.4	14
150	Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety, 2016, 25, 512-520.	1.9	14
151	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 129-140.	4.4	14
152	Cardiovascular Effectiveness of Sodiumâ€Glucose Cotransporter 2 Inhibitors and Glucagonâ€Like Peptideâ€1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. Journal of the American Heart Association, 2022, 11, e022376.	3.7	14
153	Thiazolidinedione use and ulcerative colitis-related flares: An exploratory analysis of administrative data. Inflammatory Bowel Diseases, 2011, 17, 787-794.	1.9	13
154	Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data. Pharmacoepidemiology and Drug Safety, 2013, 22, 138-144.	1.9	13
155	Short look-back periods in pharmacoepidemiologic studies of new users of antibiotics and asthma medications introduce severe misclassification. Pharmacoepidemiology and Drug Safety, 2015, 24, 478-485.	1.9	13
156	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. European Journal of Clinical Pharmacology, 2016, 72, 1013-1023.	1.9	13
157	Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. Medical Care, 2019, 57, 286-294.	2.4	13
158	Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. Depression and Anxiety, 2011, 28, 989-998.	4.1	12
159	Acute kidney injury in statin initiators. Pharmacoepidemiology and Drug Safety, 2013, 22, 1061-1070.	1.9	12
160	Measures of â€˜exposure needed for one additional patient to be harmedâ€™ in populationâ€based caseâ€control studies. Pharmacoepidemiology and Drug Safety, 2014, 23, 868-874.	1.9	12
161	Diagnostic Assessment of Assumptions for External Validity. Epidemiology, 2019, 30, 103-111.	2.7	12
162	When Is a Growth-friendly Strategy Warranted? A Matched Comparison of Growing Rods Versus Primary Posterior Spinal Fusion in Juveniles With Early-onset Scoliosis. Journal of Pediatric Orthopaedics, 2021, 41, e859-e864.	1.2	12

#	Article	IF	Citations
163	Prevalence and determinants of antibiotic resistance in faecalEscherichia coli among unselected patients attending general practitioners in Southwest Germany. Pharmacoepidemiology and Drug Safety, 2004, 13, 303-308.	1.9	11
164	Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. General Hospital Psychiatry, 2012, 34, 192-200.	2.4	11
165	Temporal Trends in Medical Therapies for ST- and Non-ST Elevation Myocardial Infarction: (from the) Tj ETQq1 1 0.784314 rgBT /Overlo 111, 305-311.	1.6	11
166	Hospitalization and Skilled Nursing Care are Predictors of Influenza Vaccination Among Patients on Hemodialysis. Medical Care, 2013, 51, 1106-1113.	2.4	11
167	Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis. Annals of Internal Medicine, 2021, 174, 737-746.	3.9	11
168	Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. Pharmacoepidemiology and Drug Safety, 2019, 28, 1609-1619.	1.9	10
169	Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children. Depression and Anxiety, 2019, 36, 179-189.	4.1	10
170	Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: A plasmode simulation. Statistics in Medicine, 2021, 40, 2101-2112.	1.6	10
171	Assessing the Impact of Propensity Score Estimation and Implementation on Covariate Balance and Confounding Control Within and Across Important Subgroups in Comparative Effectiveness Research. Medical Care, 2014, 52, 280-287.	2.4	9
172	Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1102-1110.	4.9	9
173	A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Journal of Medical Genetics, 2017, 54, 313-323.	3.2	9
174	Initiation of antihypertensive monotherapy and incident fractures among Medicare beneficiaries. Injury Epidemiology, 2017, 4, 27.	1.8	9
175	Position matters: Validation of medicare hospital claims for myocardial infarction against medical record review in the atherosclerosis risk in communities study. Pharmacoepidemiology and Drug Safety, 2018, 27, 1085-1091.	1.9	9
176	Incident Substance Use Disorder Following Anxiety Disorder in Privately Insured Youth. Journal of Adolescent Health, 2019, 65, 536-542.	2.5	9
177	The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics. Scientific Reports, 2020, 10, 17282.	3.3	9
178	Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation. Epidemiology, 2020, 31, 605-613.	2.7	9
179	Single-arm Trials With External Comparators and Confounder Misclassification. Medical Care, 2020, 58, 1116-1121.	2.4	9
180	Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. JAMA Network Open, 2021, 4, e2132215.	5.9	9

#	Article	IF	Citations
181	Epidemiologic study of analgesic abuse: Mortality study in 7275 working women (1968â€“1987). Kidney International, 1991, 40, 728-733.	5.2	8
182	Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. Journal of Geriatric Oncology, 2016, 7, 176-186.	1.0	8
183	Injection testosterone and adverse cardiovascular events: AÂcaseâ€crossover analysis. Clinical Endocrinology, 2018, 88, 719-727.	2.4	8
184	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin <scp>II</scp> Receptor Blockers after an Acute Myocardial Infarction. Pharmacotherapy, 2018, 38, 29-41.	2.6	8
185	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. Pharmacoepidemiology and Drug Safety, 2018, 27, 857-866.	1.9	8
186	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. Diabetes Care, 2019, 42, 2065-2074.	8.6	8
187	Restriction of Pharmacoepidemiologic Cohorts to Initiators of Medications in Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults. American Journal of Epidemiology, 2019, 188, 1371-1382.	3.4	8
188	Pharmacoepidemiology and Drug Safety's special issue on validation studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 123-125.	1.9	8
189	Effects of anticholinergic and sedative medication use on fractures: A <scp>selfâ€controlled</scp> design study. Journal of the American Geriatrics Society, 2021, 69, 3212-3224.	2.6	8
190	Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders. Medical Care, 2018, 56, 510-519.	2.4	7
191	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. Diabetes Care, 2020, 43, 2121-2127.	8.6	7
192	Propensity Score Estimation to Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics. PLoS ONE, 2013, 8, e63973.	2.5	7
193	Perspectives on the Future of Epidemiology: A Framework for Training. American Journal of Epidemiology, 2020, 189, 634-639.	3.4	7
194	Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data. Pharmacoepidemiology and Drug Safety, 2016, 25, 836-843.	1.9	6
195	External adjustment of unmeasured confounders in a caseâ€“control study of benzodiazepine use and cancer risk. British Journal of Clinical Pharmacology, 2017, 83, 2517-2527.	2.4	6
196	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. Diabetes Care, 2018, 41, 1196-1203.	8.6	6
197	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. Diabetes Care, 2019, 42, e89-e91.	8.6	6
198	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with typeâ€2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2096-2106.	4.4	6

#	Article	IF	Citations
199	Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposuresâ€"Beyond Avoiding Immortal Person-Time. American Journal of Epidemiology, 2019, 188, 1016-1022.	3.4	6
200	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidaseâ€4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. Diabetes, Obesity and Metabolism, 2019, 21, 854-865.	4.4	6
201	Ondansetron use in early pregnancy and the risk of miscarriage. Pharmacoepidemiology and Drug Safety, 2021, 30, 103-113.	1.9	6
202	Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. Pharmacoepidemiology and Drug Safety, 2021, 30, 114-125.	1.9	6
203	â€œThe Heidelberg Fiveâ€•personality dimensions: Genomeâ€wide associations, polygenic risk for neuroticism, and psychopathology 20â€‰years after assessment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, 77-89.	1.7	6
204	Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial. International Journal of Cancer, 2021, 149, 394-402.	5.1	6
205	Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. PLoS ONE, 2014, 9, e109433.	2.5	6
206	Impacts of Initial Prescription Length and Prescribing Limits on Risk of Prolonged Postsurgical Opioid Use. Medical Care, 2022, 60, 75-82.	2.4	6
207	Pharmacoepidemiology and â€œin silicoâ€•drug evaluation: is there common ground?. Journal of Clinical Epidemiology, 2008, 61, 205-206.	5.0	5
208	Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. Annals of Epidemiology, 2013, 23, 204-209.	1.9	5
209	Who diagnosed and prescribed what? Using provider details to inform observational research. Pharmacoepidemiology and Drug Safety, 2018, 27, 1422-1426.	1.9	5
210	Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 100-106.	1.3	5
211	1-Year Mortality and Surgery Incidence in Older US Adults with Cervical Spine Fracture. World Neurosurgery, 2020, 141, e858-e863.	1.3	5
212	Five yearsâ€™ trajectories of functionality and pain in patients after hip or knee replacement and association with long-term patient survival. Scientific Reports, 2020, 10, 14388.	3.3	5
213	Realâ€world onâ€treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. Pharmacoepidemiology and Drug Safety, 2020, 29, 832-841.	1.9	4
214	Quantifying cumulative anticholinergic and sedative drug load among US Medicare Beneficiaries. Pharmacoepidemiology and Drug Safety, 2021, 30, 144-156.	1.9	4
215	Day-of-Surgery Gabapentinoids and Prolonged Opioid Use: A Retrospective Cohort Study of Medicare Patients Using Electronic Health Records. Anesthesia and Analgesia, 2021, 133, 1119-1128.	2.2	4
216	Caseâ€“crossover and caseâ€“timeâ€“control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	4

#	Article	IF	Citations
217	A computer program to estimate power and relative efficiency to assess multiplicative interactions in flexibly matched case-control studies. Computer Methods and Programs in Biomedicine, 2004, 74, 261-265.	4.7	3
218	Strengthening Howick's Argument Against The Alleged Superiority of Placebo-Controlled Trials. American Journal of Bioethics, 2009, 9, 62-64.	0.9	3
219	ISPOR Health Policy Council Proposed Good Research Practices for Comparative Effectiveness Research: Benefit or Harm?. Value in Health, 2009, 12, 1042-1043.	0.3	3
220	International Society for Pharmacoepidemiology (ISPE) statement on American Society of Clinical Oncology's new policy for relationships with companies. Pharmacoepidemiology and Drug Safety, 2014, 23, 1-2.	1.9	3
221	Antidepressant Dose and Risk of Deliberate Self-harmâ€"Reply. JAMA Internal Medicine, 2015, 175, 464.	5.1	3
222	Approaches to Address Premature Death of Patients When Assessing Patterns of Use of Health Care Services After an Index Event. Medical Care, 2018, 56, 619-625.	2.4	3
223	Effectiveness of adjuvant <scp>FOLFOX</scp> vs <scp>5FU</scp>/<scp>LV</scp> in adults over age 65 with stage <scp>II</scp> and <scp>III</scp> colon cancer using a novel hybrid approach. Pharmacoepidemiology and Drug Safety, 2020, 29, 1579-1587.	1.9	3
224	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107706.	2.3	3
225	Longâ€Term Mortality of Patients With Osteoarthritis After Joint Replacement: Prognostic Value of Preoperative and Postoperative Pain and Function. Arthritis Care and Research, 2023, 75, 869-875.	3.4	3
226	Veterinary antimicrobial prescribing practices for treatment of presumptive sporadic urinary tract infections in dogs examined at primary care practices in the United States (2010â€"2019). Journal of the American Veterinary Medical Association, 2022, , 1-7.	0.5	3
227	Alternative analytic and matching approaches for the prevalent newâ€user design: A simulation study. Pharmacoepidemiology and Drug Safety, 2022, 31, 796-803.	1.9	3
228	Use of Combination Antihypertensive Therapy Initiation in Older Americans without Prevalent Cardiovascular Disease. Journal of the American Geriatrics Society, 2014, 62, 1729-1735.	2.6	2
229	The challenges of comparing results between placebo controlled randomized trials and nonâ€experimental new user, active comparator cohort studies: the example of olmesartan. Pharmacoepidemiology and Drug Safety, 2014, 23, 357-360.	1.9	2
230	More realistic power estimation for new user, active comparator studies: an empirical example. Pharmacoepidemiology and Drug Safety, 2016, 25, 462-466.	1.9	2
231	Using Procedure Codes to Define Radiation Toxicity in Administrative Data. Medical Care, 2017, 55, e36-e43.	2.4	2
232	Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. Pharmacoepidemiology and Drug Safety, 2017, 26, 666-675.	1.9	2
233	Comparative Propensity-Weighted Mortality After Isolated Acute Traumatic Axis Fractures in Older Adults. Geriatric Orthopaedic Surgery and Rehabilitation, 2020, 11, 215145932091186.	1.4	2
234	Methodologies for Validation of Diagnoses in Real-World Data: BONESâ€"A Case Study. Journal of Orthopaedic Trauma, 2021, 35, S28-S32.	1.4	2

#	Article	IF	Citations
235	Incidence of venous thromboembolism following initiation of non-steroidal anti-inflammatory drugs in U.S. women. Rheumatology, 2020, 59, 2502-2511.	1.9	2
236	Considerations for Observational Study Design: Comparing the Evidence of Opioid Use between Electronic Health Records and Insurance Claims.. Pharmacoepidemiology and Drug Safety, 2022, , .	1.9	2
237	Estrogens and breast cancer: does timing really matter?. Journal of Clinical Epidemiology, 2004, 57, 763-765.	5.0	1
238	Is the Whole Greater Than the Sum of Its Parts?. Journal of Rheumatology, 2010, 37, 1794-1796.	2.0	1
239	Comparative Health-Care Cost Advantage of Ipratropium over Tiotropium in COPD Patients. Value in Health, 2012, 15, 269-276.	0.3	1
240	Model Misspecification When Excluding Instrumental Variables from PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment. Epidemiologic Methods, 2014, 3, 83-96.	0.9	1
241	Trends and Determinants of Oral Anti-Diabetic Initiation in Youth with Suspected Type 2 Diabetes. PLoS ONE, 2015, 10, e0140611.	2.5	1
242	Misinterpretation of the Comparative Safety of Testosterone Dosage Formsâ€"Reply. JAMA Internal Medicine, 2015, 175, 1875.	5.1	1
243	The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. Pharmacoepidemiology and Drug Safety, 2017, 26, 446-458.	1.9	1
244	Principles and considerations for effective academia-industry collaboration in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2018, 27, 1153-1156.	1.9	1
245	Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiology and Drug Safety, 2019, 28, 305-314.	1.9	1
246	Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events. Clinical Drug Investigation, 2020, 40, 747-754.	2.2	1
247	Gender Disparities in Surgical Treatment of Axis Fractures in Older Adults. Global Spine Journal, 2021, 11, 71-75.	2.3	1
248	Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infection. BJPsych Open, 2021, 7, e188.	0.7	1
249	Aspirin and Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: Weighing the Evidence. Annals of Internal Medicine, 2007, 147, 674.	3.9	0
250	Medicaid and Medicare. Springer Series on Epidemiology and Public Health, 2021, , 231-242.	0.5	0
251	Unmeasured confounding with and without randomization. , 2021, , 185-205.		0
252	Using randomized trial data to estimate effects of complex treatment regimens in real-world patients.. Journal of Clinical Oncology, 2021, 39, e18706-e18706.	1.6	0

#	Article	IF	Citations
253	Comparing FOLFOX delivery in trial and real-world populations using longitudinal cumulative dose.. Journal of Clinical Oncology, 2021, 39, 1521-1521.	1.6	0
254	Initial therapy with transarterial chemoembolization (TACE) versus Yttrium⁹⁰ radioembolization (Y⁹⁰) for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2014, 32, e15131-e15131.	1.6	0
255	Comparative effectiveness of contemporary adjuvant chemotherapy among older rectal cancer patients.. Journal of Clinical Oncology, 2014, 32, 3579-3579.	1.6	0
256	Moving from immune phenotyping of colorectal cancer to mechanistic insights on aspirin use. Translational Cancer Research, 2016, 5, S1131-S1134.	1.0	0
257	Longitudinal cumulative dose: A novel measure to assess multiple dimensions of chemotherapy adherence over time.. Journal of Clinical Oncology, 2020, 38, 3522-3522.	1.6	0
258	Effectiveness of adjuvant FOLFOX versus 5FU for colon cancer treatment in community oncology practice using a hybrid study approach.. Journal of Clinical Oncology, 2020, 38, 7067-7067.	1.6	0
259	Comparison of approaches for measuring adherence and persistence to oral oncologic therapies in patients diagnosed with metastatic renal cell carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.0341.2021.	2.5	0
260	A computer program to estimate power and relative efficiency of flexibly matched case-control studies. Methods of Information in Medicine, 2005, 44, 693-6.	1.2	0
261	The impact of diabetes on the performance of skeletal muscle density (SMD) in screening for frailty: Findings from the Cancer and Aging Resilience Evaluation (CARE) Registry.. Journal of Clinical Oncology, 2022, 40, 12037-12037.	1.6	0